Xiling Shen

Xiling Shen is the Chief Scientific Officer at the Terasaki Institute for Biomedical Innovation (TIBI) in Los Angeles. He joined TIBI in November 2021, bringing extensive experience in biomedical engineering, computational techniques, cancer biology, and multi-omics methodologies.12

Academic and Professional Background

• Education: Dr. Shen earned his BS, MS, and PhD degrees from Stanford University. He also received the NSF Junior Faculty Career Award while at Cornell University.2
• Previous Roles: Before joining TIBI, he was the Hawkins Family Associate Professor at Duke University's Pratt School of Engineering and directed the Woo Center for Big Data and Precision Health. He was involved with the Duke Cancer Institute and the Center for Genomics and Computational Biology.123

Research Focus

Dr. Shen's research primarily revolves around:

• Precision Medicine: His lab studies cancer, stem cells, and the gut-brain axis using systems biology approaches.
• Innovative Technologies: He is known for developing droplet organoid technology termed micro-organospheres (MOS), which has applications in clinical diagnostics and ongoing clinical trials.23
• Cancer Metastasis: His work has revealed metabolic and epigenetic reprogramming in metastatic colorectal cancer, leading to new therapeutic strategies.23

Entrepreneurial Ventures

In addition to his academic roles, Dr. Shen is the founder and CEO of Xilis, Inc., a precision oncology company that successfully raised $70 million in Series A financing in July 2021. The company focuses on developing MOS-based diagnostics to predict patient outcomes.12

Contributions to Science

Dr. Shen has held significant positions in various scientific committees and consortia, including chairing conferences related to cancer research. His contributions aim to bridge the gap between laboratory research and clinical application, enhancing personalized medicine approaches for cancer treatment.13

Dr. Shen's multidisciplinary expertise positions him as a key figure in advancing biomedical innovation at TIBI, where he oversees new scientific initiatives and supports entrepreneurial efforts to translate technology into practical medical solutions.12